316 related articles for article (PubMed ID: 25312239)
1. Umeclidinium for the treatment of chronic obstructive pulmonary disease.
Segreti A; Calzetta L; Rogliani P; Cazzola M
Expert Rev Respir Med; 2014 Dec; 8(6):665-71. PubMed ID: 25312239
[TBL] [Abstract][Full Text] [Related]
2. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
Kelly E
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
[TBL] [Abstract][Full Text] [Related]
3. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Feldman GJ; Edin A
Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
Ramadan WH; Al Masri S; Rizk J
Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190
[TBL] [Abstract][Full Text] [Related]
5. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.
Cazzola M; Segreti A; Matera MG
Drug Des Devel Ther; 2013; 7():1201-8. PubMed ID: 24143077
[TBL] [Abstract][Full Text] [Related]
6. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
Blair HA; Deeks ED
Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
[TBL] [Abstract][Full Text] [Related]
8. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
Donohue JF; Singh D; Munzu C; Kilbride S; Church A
Respir Med; 2016 Mar; 112():65-74. PubMed ID: 26797016
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
10. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
Davidson JF; Donohue JF; Ohar JA
Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
13. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
Condreay L; Huang L; Harris E; Brooks J; Riley JH; Church A; Ghosh S
Respir Med; 2016 May; 114():123-6. PubMed ID: 27109822
[TBL] [Abstract][Full Text] [Related]
14. ▼Umeclidinium: another LAMA for COPD.
Drug Ther Bull; 2015 Jul; 53(7):81-4. PubMed ID: 26159701
[TBL] [Abstract][Full Text] [Related]
15. Umeclidinium/vilanterol fixed-dose combination for COPD.
Gras J
Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
[TBL] [Abstract][Full Text] [Related]
16. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P; Ciabattoni G
J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
18. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
Manickam R; Asija A; Aronow WS
Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
[TBL] [Abstract][Full Text] [Related]
19. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
Malerba M; Morjaria JB; Radaeli A
Int J Chron Obstruct Pulmon Dis; 2014; 9():687-95. PubMed ID: 25061288
[TBL] [Abstract][Full Text] [Related]
20. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.
Pleasants RA; Wang T; Gao J; Tang H; Donohue JF
Drugs; 2016 Mar; 76(3):343-61. PubMed ID: 26755180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
